Journal of Vaccine Research 2024, Vol.14, No.3, 107-119 http://medscipublisher.com/index.php/jvr 118 Lavanchy D., and Kane M., 2016, Global epidemiology of hepatitis B virus infection, Hepatitis B Virus in Human Diseases, 2006: 187-203. https://doi.org/10.1007/978-3-319-22330-8_9 Locarnini S., Hatzakis A., Chen D., and Lok A., 2015, Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs, Journal of Hepatology, 62(Suppl): S76-S86. https://doi.org/10.1016/j.jhep.2015.01.018 PMid:25920093 MacLachlan J., and Cowie B., 2015, Hepatitis B virus epidemiology, Cold Spring Harbor Perspectives in Medicine, 5(5): a021410. https://doi.org/10.1101/cshperspect.a021410. PMid:25934461 PMCid:PMC4448582 Margolis H., Alter M., and Hadler S., 1991, Hepatitis B: evolving epidemiology and implications for control, Seminars in Liver Disease, 11: 84-92. https://doi.org/10.1055/s-2008-1040427 PMid:1832236 Mcaleer W., Buynak E., Maigetter R., Wampler D., Miller W., and Hilleman M., 1984, Human hepatitis B vaccine from recombinant yeast, Nature, 307: 178-180. https://doi.org/10.1038/307178a0 PMid:6318124 Mokaya J., McNaughton A., Hadley M., Beloukas A., Geretti A., Goedhals D., and Matthews P., 2018, A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action, PLoS Neglected Tropical Diseases, 12(8): e0006629. https://doi.org/10.1371/journal.pntd.0006629 PMid:30080852 PMCid:PMC6095632 Nayagam S., Thursz M., Sicuri E., Conteh L., Wiktor S., Low-Beer D., and Hallett T., 2016, Requirements for global elimination of hepatitis B: a modelling study, The Lancet Infectious diseases, 16(12): 1399-1408. https://doi.org/10.1016/S1473-3099(16)30204-3 PMid:27638356 Oh F., 1990, Hepatitis B in Latin America: epidemiological patterns and eradication strategy, the Latin American regional study group, Vaccine, 8(Suppl): S100-S106. https://doi.org/10.1016/0264-410X(90)90228-E Ott J., Stevens G., Groeger J., and Wiersma S., 2012, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, 30(12): 2212-2229. https://doi.org/10.1016/j.vaccine.2011.12.116 Pattyn J., Hendrickx G., Vorsters A., and Damme P., 2021, Hepatitis B vaccines, The Journal of Infectious Diseases, 224: S343-S351. Razavi-Shearer D., Gamkrelidze I., Nguyen M., Chen D., Damme P., Abbas Z., Abdulla M., Rached A., Adda D., Aho I., Akarca U., Hasan F., Lawati F., Naamani K., Al-Ashgar H., Alavian S., Alawadhi S., Albillos A., Al-Busafi S., Aleman S., Alfaleh F., Aljumah A., Anand A., Anh N., Arends J., Arkkila P., Athanasakis K., Bane A., Ben‐Ari Z., Berg T., Bizri A., Blach S., Mello C., Brandon S., Bright B., Bruggmann P., Brunetto M., Buti M., Chan H., Chaudhry A., Chien R., Choi M., Christensen P., Chuang W., Chulanov V., Clausen M., Colombo M., Cornberg M., Cowie B., Craxì A., Croes E., Cuellar D., Cunningham C., Desalegn H., Dražilová S., Duberg A., Egeonu S., El-Sayed M., Estes C., Falconer K., Ferraz M., Ferreira P., Flisiak R., Fraňková S., Gaeta G., García-Samaniego J., Genov J., Gerstoft J., Goldiş A., Gountas I., Gray R., Pessoa M., Hajarizadeh B., Hatzakis A., Hézode C., Himatt S., Hoepelman A., Hrstic I., Hui Y., Husa P., Jahis R., Janjua N., Jarčuška P., Jaroszewicz J., Kaymakoğlu S., Kershenobich D., Kondili L., Konysbekova A., Krajden M., Kristian P., Laleman W., Lao W., Layden J., Lazarus J., Lee M., Liakina V., Lim Y., Loo C., Lukšić B., Malekzadeh R., Malu A., Mamatkulov A., Manns M., Marinho R., Maticic M., Mauss S., Memon M., Correa M., Méndez-Sánchez N., Merat S., Metwally A., Mohamed R., Mokhbat J., Moreno C., Mossong J., Mourad F., Müllhaupt B., Murphy K., Musabaev E., Nawaz A., Nde H., Negro F., Nersesov A., Nguyen V., Njouom R., Ntagirabiri R., Nurmatov Z., Obekpa S., Ocama P., Oguche S., Omede O., Omuemu C., Opare-Sem O., Opio C., Örmeci N., Papatheodoridis G., Pasini K., Pimenov N., Poustchi H., Quang T., Qureshi H., Ramji A., Razavi-Shearer K., Redae B., Reesink H., Ríos C., Rjašková G., Robbins S., Roberts L., Roberts S., Ryder S., Safadi R., Sagalova O., Salupere R., Sanai F., Sánchez-Ávila J., Saraswat V., Sarrazin C., Schmelzer J., Schréter I., Scott J., Seguin-Devaux C., Shah S., Sharara A., Sharma M., Shiha G., Shin T., Sievert W., Sperl J., Stärkel P., Stedman C., Sypsa V., Tacke F., Tan S., Tanaka J., Tomasiewicz K., Urbánek P., Meer A., Vlierberghe H., Vella S., Vince A., Waheed Y., Waked I., Walsh N., Weis N., Wong V., Woodring J., Yaghi C., Yang H., Yang C., Yesmembetov K., Yosry A., Yuen M., Yusuf M., Zeuzem S., and Razavi H., 2018, Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study, The Lancet Gastroenterology and Hepatology, 3(6): 383-403. Rahmani A., Montecucco A., Vitturi B., Debarbieri N., Dini G., and Durando P., 2022, Long-term effectiveness of hepatitis B vaccination in the protection of healthcare students in highly developed countries: a systematic review and meta-analysis, Vaccines, 10(11): 1841. https://doi.org/10.3390/vaccines10111841 Rottinghaus S., Poland G., Jacobson R., Barr L., and Roy M., 2003, Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination, Vaccine, 21(31): 4604-4608. https://doi.org/10.1016/S0264-410X(03)00447-X Shepard C., Simard E., Finelli L., Fiore A., and Bell B., 2006, Hepatitis B virus infection: epidemiology and vaccination, Epidemiologic Reviews, 28: 112-125. Spearman C., Spearman C., Afihene M., Ally R., Apica B., Awuku Y., Cunha L., Dusheiko G., Gogela N., Gogela N., Kassianides C., Kew M., Kew M., Lam P., Lesi O., Lohouès-Kouacou M., Mbaye P., Musabeyezu E., Musau B., Os O., Rwegasha J., Scholz B., Shewaye A., Tzeuton C., Sonderup M., and Sonderup M., 2017, Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets, The Lancet, Gastroenterology and Hepatology, 2(12): 900-909. https://doi.org/10.1016/S2468-1253(17)30295-9
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==